Altimmune, Inc., a late clinical stage biopharmaceutical company, focuses on developing novel therapies for serious liver diseases. Its lead product candidate is pemvidutide, a GLP-1/glucagon dual receptor agonist, which is in Phase 3 clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis, alcohol use disorder, and alcohol-associated liver disease. The company was founded in 1997 and is headquartered in Gaithersburg, Maryland.
| Business Activity | PASS |
| Debt Ratio (0.06%) | PASS |
| Cash Ratio (0.47%) | FAIL |
| Receivables Ratio (0.00%) | PASS |
| Revenue Ratio (0.00%) | PASS |
| Overall | FAIL |
| Date | EPS Est. | Reported EPS | Surprise % |
|---|---|---|---|
| 2026-08-11 | -0.16 | Pending | -- |
| 2026-05-13 | -0.25 | -0.18 | +28.0% |
| 2026-03-05 | -0.24 | -0.27 | -11.2% |
| 2025-11-06 | -0.27 | -0.21 | +21.0% |
| 2025-08-12 | -0.32 | -0.27 | +15.8% |
| 2025-05-13 | -0.34 | -0.26 | +23.9% |
| 2025-02-27 | -0.34 | -0.33 | +1.5% |
| 2024-11-12 | -0.36 | -0.32 | +10.5% |
| Period | Revenue | Net Income | EBITDA | Gross Profit | Op. Income | EPS |
|---|---|---|---|---|---|---|
| 2026-03-31 | — | -$22.6M | -$21.5M | — | -$24.2M | -0.18 |
| 2025-12-31 | $26.0K | -$27.4M | -$26.5M | — | -$28.9M | -0.27 |
| 2025-09-30 | $5.0K | -$19.0M | -$18.5M | — | -$20.9M | -0.21 |
| 2025-06-30 | $5.0K | -$22.1M | -$21.9M | — | -$22.9M | -0.27 |
| 2025-03-31 | $5.0K | -$19.6M | -$20.2M | — | -$21.8M | -0.26 |
| Date | Name | Role | Shares | Value |
|---|---|---|---|---|
| 2026-04-06 | GILL JOHN M | Director | 9,200 | $31.4K |
| 2026-04-01 | WEAVER GREGORY L | Chief Financial Officer | 10,000 | $31.5K |
| 2026-04-01 | DURSO JEROME BENEDICT | Chief Executive Officer | 15,000 | $47.1K |
| 2026-03-06 | WEAVER GREGORY L | Chief Financial Officer | 5,000 | $17.7K |
| 2026-03-06 | DURSO JEROME BENEDICT | Chief Executive Officer | 20,000 | $70.8K |
| 2026-02-02 | ROBERTS M SCOT | Officer | 17,050 | -- |
| 2026-01-30 | GARG VIPIN K. | Director | 26,775 | -- |
| 2026-01-30 | ROBERTS M SCOT | Officer | 5,567 | $31.2K |
| 2026-01-30 | GARG VIPIN K. | Director | 6,926 | $38.8K |
| 2026-01-30 | JORDT RAYMOND M | Officer | 4,571 | $25.6K |
| Holder | Shares | Value | % Held |
|---|---|---|---|
| Blackrock Inc. | 12.8M | $37.1M | 0.1% |
| State Street Corporation | 7.1M | $20.7M | 0.0% |
| Vanguard Capital Management LLC | 5.7M | $16.4M | 0.0% |
| Vanguard Portfolio Management LLC | 5.4M | $15.6M | 0.0% |
| Marshall Wace LLP | 4.0M | $11.7M | 0.0% |
| Millennium Management Llc | 3.3M | $9.4M | 0.0% |
| Geode Capital Management, LLC | 3.1M | $9.0M | 0.0% |
| Alyeska Investment Group, L.p. | 2.6M | $7.7M | 0.0% |
| Two Sigma Investments, LP | 2.5M | $7.2M | 0.0% |
| Nuveen, LLC | 2.3M | $6.8M | 0.0% |
$268.3M
1.33
0.173
8
$36.0K
$35.8M
1.60
7.56
0.2%
57
| Date | Estimate | Reported | Surprise |
|---|---|---|---|
| 2026-08-11 | $-0.16 | Pending | — |
| 2026-05-13 | $-0.25 | $-0.18 | +28.0% |
| 2026-03-05 | $-0.24 | $-0.27 | -11.2% |
| 2025-11-06 | $-0.27 | $-0.21 | +21.0% |
| 2025-08-12 | $-0.32 | $-0.27 | +15.8% |
| 2025-05-13 | $-0.34 | $-0.26 | +23.9% |
| Shares | Cost | Profit to Target | R:R |
|---|---|---|---|
| To Consensus ($16.06, 9 analysts) | |||
| 10 | $29.75 | +$130.80 (440%) | 29.1R |
| 50 | $148.75 | +$654.00 (440%) | 29.1R |
| 100 | $297.50 | +$1,308.00 (440%) | 29.1R |
- Elevated short interest (7.56 days to cover)
A single score combining all analytical layers below. A is strongest, D is weakest.
How much could this ticker lose on a bad day? These metrics measure worst-case scenarios from historical data.
Based on 10,000 simulated price paths, here is the probability of where this ticker could be in 30, 60, and 90 days.
What direction is this ticker actually moving, filtered through noise? Is it speeding up or slowing down?
Classic chart signals that institutional traders monitor. Golden Cross is bullish, Death Cross is bearish.
Is this company financially sound? The Z-Score measures bankruptcy risk. The F-Score measures fundamental strength.
These tickers tend to move together (positive) or in opposite directions (negative). Useful for portfolio diversification.
| Ticker | Correlation |
|---|---|
| XNCR | 0.365 |
| ARKG | 0.355 |
| DNLI | 0.352 |
| HQH | 0.333 |
| CLDX | 0.319 |
| Ticker | Correlation |
|---|---|
| LIVE | -0.225 |
| SUKOONTAKAFL.AE | -0.207 |
| SPEC.KW | -0.174 |
| MCCS.QA | -0.149 |
| SENEB | -0.139 |
Does this ticker have consistent patterns on certain days or months? Historical tendencies, not guarantees.
After this company beats earnings, does the price keep going up? Drift tracks post-earnings momentum.
How does this ticker's recent performance compare to the entire universe? Ranked across 1, 3, 6, and 12-month returns.